Loading company…
Tokyo-based developer of AI diagnostic tools, including RS5614 and RS8001, for hospitals and diagnostic laboratories.
Founded in 2000 and headquartered in Tokyo, Japan, Renascience, Inc. develops AI applications for medical diagnostics, aimed at early disease detection and personalized treatment planning. Its products are sold directly to healthcare providers, often through bulk purchases or subscriptions. On September 24, 2021, the company raised JPY 2 billion through an IPO, selling 3 million shares at JPY 670 per share on the Tokyo Stock Exchange Mother's section, valuing it at JPY 8.2 billion.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in